Friday 6 November 2026
Export BSX’s income statement to Excel — free account
Boston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.
- Revenue
- +1.44%
- EPS
- −21.5%
- Free cash flow
- −25.3%
- Total debt
- +3.04%
Quarter to September 2026, against a year earlier
42.73
1.91
−4.28%
Follow BSX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 7 | 8 | 7 |
+8 more TTM periods Free account |
| 14.15% | 15.37% | 14.69% | 12.47% | ||
| 7.94% | 8.47% | 8.44% | 6.98% | ||
ROIC |
6.60% | 6.96% | 6.64% | 6.65% | |
Return on Tangible Assets |
55.02% | 64.81% | 43.60% | 39.21% | |
Average Days of Receivables |
53.93 | 53.01 | 53.60 | 53.20 | |
Free Cash Flow per Share |
2.30 | 2.47 | 2.34 | 2.47 | |
Free Cash Flow |
3,331.00 | 3,625.00 | 3,475.00 | 3,658.00 | |
Capital Expenditures |
(903.00) | (904.00) | (866.00) | (876.00) | |
| Other line items | |||||
Cash ROIC |
8.67% | 9.46% | 9.01% | 9.66% | |
Accounts Receivable Turnover |
7.09 | 7.16 | 7.21 | 7.32 | |
Accounts Payable Turnover |
5.77 | 5.76 | 5.93 | 5.91 | |
Inventory Turnover |
2.08 | 2.07 | 2.13 | 2.16 | |
Average Days of Payables |
70.17 | 71.15 | 65.50 | 67.12 | |
Days of Inventory on Hand |
186.21 | 186.98 | 178.94 | 172.67 | |
Tax Rate |
(0.04) | (0.05) | (0.05) | (0.15) | |
Research and Development Expense of Revenue |
10.25% | 10.25% | 10.31% | 10.22% | |
Selling, General and Administrative Expense of Revenue |
33.90% | 34.29% | 34.52% | 34.54% | |
Share Based Compensation of Revenue |
1.49% | 1.52% | 1.49% | 1.49% | |
Interest Coverage |
10.45 | 11.43 | 10.61 | 10.35 | |
Operating CF/Net income |
1.21 | 1.23 | 1.22 | 1.56 | |
Depreciation/Fixed assets |
0.35 | 0.34 | 0.35 | 0.35 | |
Capex/Depreciation |
(0.61) | (0.64) | (0.60) | (0.62) | |
Revenue per Share |
14.54 | 14.28 | 13.88 | 13.56 | |
Operating CF per Share |
2.92 | 3.08 | 2.92 | 3.06 | |
Capex per Share |
(0.62) | (0.61) | (0.58) | (0.59) | |
Capex to Sales |
0.04 | 0.04 | 0.04 | 0.04 |
Columns are period end dates · fundamentals updated 6 Nov 2026